Yifan Pharmaceutical Co., Ltd.
↗Hangzhou, China
Yifan Pharmaceutical is a diversified Chinese pharmaceutical company headquartered in Hangzhou focused on research, development, manufacturing, and commercialization of innovative biopharmaceutical products. The company operates four main business segments: biologic products, small molecules, synthetic biologics, and special traditional Chinese medicines (TCMs). With 5 research centers located in San Francisco, Shanghai, Beijing, Hangzhou, and Hefei, plus manufacturing facilities across China and internationally, Yifan serves patients in over 40 countries globally. The company has approximately 2,000 employees including 500 overseas, and has established itself as a significant player in bringing Chinese-developed innovative drugs to global markets through subsidiaries like Evive Biotech.
CLASSIFICATION
SIZE & FINANCIALS
Employees:1001-5000
Revenue:$700M-$800M USD (~5.2B CNY in 2024)
Founded:1994
Ownership:public
Status:operating
FUNDING
Stage:Public
STOCK
Exchange:Shenzhen Stock Exchange (SZSE)
Ticker:002019.SZ
Market Cap:~18.2-19.1B CNY (~$2.5-2.7B USD estimate)
PIPELINE
Stage:Phase 2-3, Commercial
Lead Drug Stage:Commercial - Ryzneuta (FDA, EMA, NMPA approved)
Modalities:Monoclonal antibodies (mAb), Small molecules, Biosimilars, Biologic proteins, Synthetic biologics, Gene therapy, Traditional Chinese medicines
Active Trials:20
Trial Phases:-
FDA Approvals:3
EMA Approvals:1
CORPORATE STRUCTURE
Subsidiaries:Evive Biotech (US-based, handles global commercialization), Bioton (Poland, insulin products), SciGen (acquired, provides Asia Pacific distribution network)
Key Partnerships:Evive Biotech & Lenis farmacevtika - Ryzneuta distribution in Balkans (Slovenia, Croatia, Bosnia, Serbia, North Macedonia, Montenegro, Albania, Kosovo), Evive & APOGEPHA - Ryzneuta commercialization in Germany, SciGen partnerships - Sandoz Corp., Novartis International AG, Merck & Co. Inc., Distribution agreements across 40+ countries/regions in Southeast Asia, Europe, North America
COMPETITION
Position:Challenger/Niche Player - strong position in China and Asian markets, growing global presence via partnerships
Competitors:Junshi Biosciences, Hengrui Medicine, Fosun Pharma, Xinda Bio, Other Chinese innovative biotech/pharma companies, International pharma in oncology/hematology (Amgen, Pfizer, Merck, BMS, AbbVie)
LEADERSHIP
Key Executives:
Xianfeng Cheng - Executive (specific title not publicly detailed)
LINKS
Website:yifanyy.com
Crunchbase:Crunchbase Profile
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Yifan Pharmaceutical Co., Ltd.. The information on this page was collected and compiled using AI agents from publicly available sources. While we strive for accuracy, this data may be incomplete, outdated, or contain errors. For official information, please visit the company's website directly. If you notice any inaccurate information, please contact us.